CO6190529A2 - Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a - Google Patents

Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a

Info

Publication number
CO6190529A2
CO6190529A2 CO09002429A CO09002429A CO6190529A2 CO 6190529 A2 CO6190529 A2 CO 6190529A2 CO 09002429 A CO09002429 A CO 09002429A CO 09002429 A CO09002429 A CO 09002429A CO 6190529 A2 CO6190529 A2 CO 6190529A2
Authority
CO
Colombia
Prior art keywords
substituted
independently
different substituents
hydrogen atom
same
Prior art date
Application number
CO09002429A
Other languages
English (en)
Inventor
Yoshikazu Iwasawa
Tetsuya Kato
Nobuhiko Kawanishi
Kouta Masatani
Takashi Mita
Katsumasa Nonoshita
Mitsuru Ohkubo
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of CO6190529A2 publication Critical patent/CO6190529A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • C07D241/22Benzenesulfonamido pyrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

1.- Un compuesto de fórmula general I:en la que: R1 es a un átomo de hidrógeno, F, CN, COORa1, CONRa2Ra2´, NRa3CORa3´, CONRa4ORa4', NRa5CONRa5'Ra5", NRa6COORa6', SO2NRa7Ra7', NRa8SO2Ra8', CORa9, SO2Ra10, NO2, ORa11, o NRa12Ra12´, en los que: Ra1, Ra3, Ra4, Ra5, Ra6 y Ra8 son cada uno independientemente un átomo de hidrógeno o alquilo inferior;Ra2, Ra2', Ra5', Ra5", Ra7, Ra7', Ra12 y Ra12' son cada uno independientemente un átomo de hidrógeno o alquilo inferior que puede estar sustituido con uno o más de los mismos o diferentes sustituyentes seleccionados del grupo , en el que es un átomo de halógeno, hidroxi, nitro, ciano, amino, carbamoílo, aminosulfonilo, imino, alquilamino inferior, dialquilamino inferior, alquilsulfonilo inferior, alquilsulfonilamino inferior, alcoxi inferior, alcoxicarbonilo inferior, alcoxicarbonilamino inferior, alcanoílo inferior, alcanoiloxi inferior, alquiltio inferior y carboxilo; con tal de, sin embargo, que Ra2 y Ra2'; Ra5' y Ra5"; Ra7 y Ra7´; Ra12 y Ra12' cada uno independientemente, junto con el átomo de nitrógeno al cual se unen, pueda formar un grupo heterocíclico aromático o alifático de 5 ó 6 miembros que puede estar sustituido con uno o más de los mismos o diferentes sustituyentes seleccionados del , en el que es un átomo de halógeno, hidroxi, amino e hidroximetilo; Ra3', Ra4', Ra6', Ra8', Ra9, Ra10 y Ra11 son cada uno independientemente un átomo de hidrógeno o alquilo inferior que puede estar sustituido con uno o más de los mismos o diferentes sustituyentes seleccionados del grupo ; o R1 es un alquilo inferior que puede estar sustituido con uno o más de los mismos o diferentes sustituyentes ...
CO09002429A 2006-08-31 2009-01-14 Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a CO6190529A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006236472 2006-08-31
US92608607P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
CO6190529A2 true CO6190529A2 (es) 2010-08-19

Family

ID=39136042

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09002429A CO6190529A2 (es) 2006-08-31 2009-01-14 Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a

Country Status (27)

Country Link
US (2) US7915263B2 (es)
EP (2) EP2062887B1 (es)
JP (3) JP2008081492A (es)
KR (1) KR20090055562A (es)
CN (1) CN101528731B (es)
AR (1) AR062585A1 (es)
AU (1) AU2007289609B2 (es)
CA (1) CA2657469C (es)
CL (1) CL2007002519A1 (es)
CO (1) CO6190529A2 (es)
CR (1) CR10553A (es)
EC (1) ECSP099062A (es)
ES (1) ES2389515T3 (es)
GT (1) GT200900008A (es)
HN (1) HN2009000113A (es)
IL (1) IL196497A0 (es)
MA (1) MA30719B1 (es)
MX (1) MX2009000390A (es)
NO (1) NO20091301L (es)
NZ (1) NZ574081A (es)
PE (1) PE20080835A1 (es)
RU (1) RU2437880C2 (es)
SV (1) SV2009003152A (es)
TW (1) TW200817363A (es)
UA (1) UA95972C2 (es)
WO (2) WO2008026769A1 (es)
ZA (1) ZA200900126B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2254888B1 (en) * 2008-02-22 2014-12-24 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
CA2720034A1 (en) * 2008-03-31 2009-10-08 Sun Pharmaceutical Industries Ltd. An improved process for the preparation of morphinane analogues
US20110129467A1 (en) * 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
AU2010284255B2 (en) * 2009-08-17 2016-11-17 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US9145414B2 (en) 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
US10866838B2 (en) * 2015-03-25 2020-12-15 Intel Corporation Cluster computing service assurance apparatus and method
CN108250191B (zh) * 2018-03-15 2020-10-20 兰州大学 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
ES2137932T3 (es) 1990-09-28 2000-01-01 Smithkline Beecham Corp Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス.アー. 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス.アー. 白金化合物の製造方法
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2250186T3 (es) 1999-09-10 2006-04-16 MERCK & CO., INC. Inhibidores de tirosina quinasa.
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
ATE528303T1 (de) 2000-12-21 2011-10-15 Vertex Pharma Pyrazoleverbindungen als proteinkinasehemmer
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
US7709475B2 (en) * 2004-05-21 2010-05-04 Banyu Pharmaceutical Co., Ltd. Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
US7919487B2 (en) 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US20060160869A1 (en) 2005-01-05 2006-07-20 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
JP5075624B2 (ja) * 2005-04-28 2012-11-21 田辺三菱製薬株式会社 シアノピリジン誘導体及びその医薬としての用途
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129842A1 (ja) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives

Also Published As

Publication number Publication date
EP2062887B1 (en) 2012-07-04
EP2061782A4 (en) 2010-03-31
WO2008026769A1 (fr) 2008-03-06
KR20090055562A (ko) 2009-06-02
RU2009111599A (ru) 2010-10-10
TW200817363A (en) 2008-04-16
JP2008081492A (ja) 2008-04-10
US7915263B2 (en) 2011-03-29
US20080058347A1 (en) 2008-03-06
JPWO2008026769A1 (ja) 2010-01-21
CR10553A (es) 2009-06-28
NO20091301L (no) 2009-04-30
RU2437880C2 (ru) 2011-12-27
MA30719B1 (fr) 2009-09-01
EP2062887A1 (en) 2009-05-27
MX2009000390A (es) 2009-01-29
AU2007289609A1 (en) 2008-03-06
GT200900008A (es) 2010-10-04
SV2009003152A (es) 2009-04-28
CL2007002519A1 (es) 2008-02-08
AU2007289609B2 (en) 2012-02-02
ZA200900126B (en) 2010-01-27
UA95972C2 (ru) 2011-09-26
JP2010047602A (ja) 2010-03-04
CN101528731A (zh) 2009-09-09
JP4466782B2 (ja) 2010-05-26
IL196497A0 (en) 2009-09-22
ECSP099062A (es) 2009-02-27
JP5256168B2 (ja) 2013-08-07
HN2009000113A (es) 2014-01-06
EP2061782A1 (en) 2009-05-27
AR062585A1 (es) 2008-11-19
NZ574081A (en) 2011-08-26
ES2389515T3 (es) 2012-10-26
US20100016335A1 (en) 2010-01-21
EP2062887A4 (en) 2010-03-31
WO2008026768A1 (en) 2008-03-06
PE20080835A1 (es) 2008-06-14
CA2657469C (en) 2013-07-02
CA2657469A1 (en) 2008-03-06
CN101528731B (zh) 2014-05-07

Similar Documents

Publication Publication Date Title
CO6190529A2 (es) Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a
ES2531398T3 (es) Nuevos derivados de aminopiridina que tienen una acción inhibidora selectiva de Aurora A
CO6190609A2 (es) Compuestos de urea policiclicos antibacterianos
ES2604191T3 (es) Inhibidores de tirosina quinasas
AR068764A1 (es) N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah.
CO5680435A2 (es) Derivados de quinazolina inhibidores de tirosina quinasa erbb y egb, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
CO6321239A2 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ECSP088129A (es) Derivado novedoso de heterocicliden acetamida
PE20151776A1 (es) Compuestos de heteroarilo y sus usos
ES2391373T3 (es) Derivados de quinoleína como inhibidores de la cinasa AXL
GT200600167A (es) Derivados de dihidrobenzofurano y usos de los mismos
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
CY1109610T1 (el) Παραγωγο βενζιμιδαζολης και η χρηση αυτου ως ανταγωνιστου του υποδοχεα αιι
AR068813A1 (es) Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
AR053569A1 (es) Derivados de pirazol
ES2478823T3 (es) Derivados de iminopiridina y uso de los mismos
CO5601027A2 (es) Derivados de imidazol-4-il-etinil-piridina
AR077362A1 (es) Compuestos que modulan selectivamente el receptor cb2
AR086411A1 (es) Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
NI200700313A (es) Aminopirimidinas como moduladores de la cinasa .
AR050250A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
UY31604A1 (es) Compuestos tricíclicos y uso de los mismos
AR068627A1 (es) Inhibidores de la interaccion entre mdm2 y p53
CO6210825A2 (es) Derivado de heterocicliden-n-(aril)acetamina

Legal Events

Date Code Title Description
FC Application refused